{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhou S"],"funding":["Natural Science Foundation of Chongqing Innovation Group Science Program","Military Clinical Medical Innovation Project of Xinqiao hospital","National Natural Science Foundation of China","Chongqing Science and Health Joint Medical Research Major Project","Translational Research Grant of NCRCH"],"pagination":["96-105"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11226560"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["120(1)"],"pubmed_abstract":["The conditioning regimen is an important part of autologous hematopoietic stem cell transplantation (ASCT). We explored the efficacy and safety of an optimized BEAC (adjusted-dose, intermediate-dose cytarabine and reduced-dose cyclophosphamide, AD-BEAC) conditioning regimen for non-Hodgkin lymphoma (NHL). A total of 141 NHL patients received AD-BEAC or a standard-dose BEAC (SD-BEAC) conditioning regimen from January 2007 to December 2017, and 104 patients were included in the study after 1:1 propensity matching. The 5-year overall survival (OS) and progression free survival (PFS) rates were significantly higher with AD-BEAC than with SD-BEAC (82.7% vs. 67.3%, P = 0.039; 76.9% vs. 57.7%, P = 0.039). Transplant-related mortality (TRM) was 3.8% in both the AD-BEAC and SD-BEAC groups. The AD-BEAC group had lower incidence of oral ulcers and cardiotoxicity than the SD-BEAC group. An optimized BEAC conditioning regimen is an effective conditioning regimen for ASCT in NHL with acceptable toxicity, that is more effective and safer than a standard BEAC conditioning regimen."],"journal":["International journal of hematology"],"pubmed_title":["Optimized BEAC conditioning regimen improves clinical outcomes of autologous hematopoietic stem cell transplantation in non-Hodgkin lymphomas."],"pmcid":["PMC11226560"],"funding_grant_id":["82070208","2021WWB05","2022ZDXM025","No. 81970162","2021JSLC0003","cstc2021jcyj-cxttX0001","2022DBXM003","2020ZKZC02"],"pubmed_authors":["Liu H","Li J","Lin S","Zhou S","Li F","Zhang X","Gao L","Ma X","Xiang X","Rao J","Zeng Y","Dong S"],"additional_accession":[]},"is_claimable":false,"name":"Optimized BEAC conditioning regimen improves clinical outcomes of autologous hematopoietic stem cell transplantation in non-Hodgkin lymphomas.","description":"The conditioning regimen is an important part of autologous hematopoietic stem cell transplantation (ASCT). We explored the efficacy and safety of an optimized BEAC (adjusted-dose, intermediate-dose cytarabine and reduced-dose cyclophosphamide, AD-BEAC) conditioning regimen for non-Hodgkin lymphoma (NHL). A total of 141 NHL patients received AD-BEAC or a standard-dose BEAC (SD-BEAC) conditioning regimen from January 2007 to December 2017, and 104 patients were included in the study after 1:1 propensity matching. The 5-year overall survival (OS) and progression free survival (PFS) rates were significantly higher with AD-BEAC than with SD-BEAC (82.7% vs. 67.3%, P = 0.039; 76.9% vs. 57.7%, P = 0.039). Transplant-related mortality (TRM) was 3.8% in both the AD-BEAC and SD-BEAC groups. The AD-BEAC group had lower incidence of oral ulcers and cardiotoxicity than the SD-BEAC group. An optimized BEAC conditioning regimen is an effective conditioning regimen for ASCT in NHL with acceptable toxicity, that is more effective and safer than a standard BEAC conditioning regimen.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-04T12:54:06.477Z","creation":"2025-04-04T12:54:06.477Z"},"accession":"S-EPMC11226560","cross_references":{"pubmed":["38587693"],"doi":["10.1007/s12185-024-03755-7"]}}